Ulf Holmbäck

Title: Ulf Holmbäck: Innovator in Modified Release Compositions

Introduction

Ulf Holmbäck is a notable inventor based in Uppsala, Sweden. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of modified release compositions for the treatment of obesity and related metabolic disorders. With a total of 3 patents to his name, Holmbäck's work is recognized for its innovative approach to drug formulation.

Latest Patents

Holmbäck's latest patents focus on a modified-release composition that combines orlistat and acarbose. This invention features distinct parts with varying release patterns, which include: a first part, G1, comprising from about 5 to about 70% w/w of the total dose of acarbose; a second part, G2A, comprising from about 30 to about 95% w/w of the total dose of acarbose; a third part, G2B, comprising from about 10 to about 90% w/w of the total dose of orlistat; and a fourth part, G3, comprising from about 10 to about 80% w/w of the total dose of orlistat. The total concentration of acarbose and orlistat in the composition is 100% w/w.

Career Highlights

Ulf Holmbäck is currently associated with Empros Pharma AB, where he continues to innovate in the pharmaceutical sector. His work has been instrumental in advancing treatment options for obesity, showcasing his commitment to improving health outcomes through scientific research.

Collaborations

Holmbäck has collaborated with notable colleagues such as Anders Forslund and Hans Lennernäs. These partnerships have contributed to the success of his projects and the advancement of pharmaceutical innovations.

Conclusion

Ulf Holmbäck's contributions to the field of modified release compositions highlight his role as a key innovator in pharmaceutical sciences. His work continues to pave the way for new treatment options in obesity management.